Description
Anti-CD40 ligand Antibody, Non-Fucosylated (BioBet-150ZP) is a humanized monoclonal IgG1, κ antibody against CD40 ligand. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Systemic lupus erythematosus (SLE)
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD40 ligand antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD40LG
Full Name
CD40 Ligand
Background
CD40LG (CD40 Ligand) is a Protein Coding gene.
Diseases associated with CD40LG include Immunodeficiency With Hyper-Igm, Type 1 and Cd40 Ligand Deficiency.
Among its related pathways are PEDF Induced Signaling and Cytokine Signaling in Immune system.
Gene Ontology (GO) annotations related to this gene include cytokine activity and CD40 receptor binding.
Alternative Names
toralizumab;252662-47-8;IDEC-131;E6040;IDEC 131;CD40LG;CD40 ligand;HIGM1, IMD3, TNFSF5, tumor necrosis factor (ligand) superfamily, member 5 (hyper IgM syndrome);CD40 antigen ligand;CD40L;CD154;gp39;hCD40L;hyper IgM syndrome;T B cell activating molecule;T
Gene ID
959
UniProt ID
P29965
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with CD40LG include Immunodeficiency With Hyper-Igm, Type 1 and Toxoplasmosis.
Related Pathways
Its related pathways are NF-KappaB Family Pathway and PEDF Induced Signaling.
Function
Cytokines as ligands for CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973). Co-stimulates the proliferation of T cells and the production of cytokines (PubMed: 8617933). Its cross-linking on T cells produces a co-stimulatory signal, which enhances the production of IL4 and IL10 through TCR/CD3 ligation and CD28 co-stimulation (PubMed: 8617933). Induce the activation of nf-kpa-b (PubMed: 15067037, PubMed: 31331973). Induces the activation of T cell kinases MAPK8 and PAK2 (PubMed: 15067037). Induces tyrosine phosphorylation of CD28 subtype 3 (PubMed: 15067037). Mediates b-cell proliferation in the absence of co-stimulation and mediates IgE production in the presence of IL4 (similar). Participate in the conversion of immunoglobulins (similarity).
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Immune System antibody
Post-translational modifications
The soluble form derives from the membrane form by proteolytic processing. N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40. Not O-glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-150ZP
Description
Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD40 ligand. Toralizumab was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).
Antibody Indication
Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)
